Clinical trials
Observational Carcinoma, Ovarian Epithelial trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 24 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lei Li | 9 |
| RenJi Hospital | 2 |
| Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 1 |
| Asan Medical Center | 1 |
| Cancer Research UK | 1 |
| Centre Leon Berard | 1 |
| Centro di Riferimento Oncologico - Aviano | 1 |
| Clinica Universidad de Navarra, Universidad de Navarra | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| Gynecologic Oncology Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Ovarian Epithelial | 24 |
| Ovarian Neoplasms | 6 |
| Fallopian Tube Neoplasms | 3 |
| Carcinogenesis | 1 |
| Chromosomal Instability | 1 |
| Disease | 1 |
| Hereditary Breast and Ovarian Cancer Syndrome | 1 |
| Microsatellite Instability | 1 |
| Neutropenia | 1 |
| Peritoneal Neoplasms | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.